DexTech is a Swedish research company specializing in drug development for urological oncology, primarily prostate cancer. Drug candidates are developed using CDC (carbohydrate-drug-conjugate) technology using a proprietary carbohydrate platform, GUA-Dex. The company conducts translational research and has a strong clinical foundation with specialist expertise in clinical oncology, pre-clinical research, and process development for drug manufacturing.
15 April, 2024
DexTech Medical announces new positive results from the myeloma study
15 February, 2024
Half-year report July 1 – December 31, 2023
23 January, 2024
DexTech Medical announces positive results from the myeloma study
DexTech’s patented technology platform, GuaDex, is used for our own medication development, but can also be licensed for other specific applications. The platform can be compared to building blocks, offering multiple ways of building new molecules.
Read moreDexTex has used GuaDex, its own technology platform, to develop four candidate medications: OsteoDex, SomaDex, CatDex and PSMA-Dx.
Read more